Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2015
Period Ending	Nov '24 Nov 21, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2015
Market Capitalization	4,838	2,224	1,563	1,606	818	276	Upgrade
Market Cap Growth	74.83%	42.30%	-2.70%	96.45%	196.48%	175.69%	Upgrade
Enterprise Value	4,775	2,144	1,482	1,572	801	270	Upgrade
Last Close Price	14.40	6.88	4.72	5.68	3.00	1.02	Upgrade
PE Ratio	-	626.44	-	-	-	-	Upgrade
PS Ratio	9.65	6.49	14.37	290.85	203.32	112.65	Upgrade
PB Ratio	15.43	21.91	28.75	1023.78	13.41	5.60	Upgrade
P/TBV Ratio	1387.98	83.14	109.40	-	53.46	13.95	Upgrade
P/FCF Ratio	162.55	229.72	-	-	619.12	-	Upgrade
P/OCF Ratio	125.41	136.63	-	-	540.78	-	Upgrade
EV/Sales Ratio	11.36	6.26	13.62	284.54	199.24	110.26	Upgrade
EV/EBITDA Ratio	98.30	55.00	-	-	-	-	Upgrade
EV/EBIT Ratio	108.88	60.60	-	-	-	-	Upgrade
EV/FCF Ratio	186.64	221.37	-	-	606.68	-	Upgrade
Debt / Equity Ratio	0.05	0.12	0.13	1.18	0.03	0.03	Upgrade
Debt / EBITDA Ratio	0.30	0.30	-	-	-	-	Upgrade
Debt / FCF Ratio	0.58	1.23	-	-	1.29	-	Upgrade
Asset Turnover	1.22	1.54	0.88	0.06	0.04	0.04	Upgrade
Inventory Turnover	11.07	14.59	10.92	1.25	3.45	4.29	Upgrade
Quick Ratio	0.81	1.24	1.90	1.13	4.62	5.42	Upgrade
Current Ratio	0.99	1.43	2.02	1.25	4.69	5.52	Upgrade
Return on Equity (ROE)	20.49%	4.55%	-253.34%	-198.36%	-60.21%	-45.32%	Upgrade
Return on Assets (ROA)	7.97%	9.92%	-25.37%	-37.95%	-23.64%	-28.06%	Upgrade
Return on Capital (ROIC)	16.34%	25.26%	-97.35%	-118.20%	-40.13%	-39.67%	Upgrade
Earnings Yield	0.79%	0.16%	-4.53%	-3.64%	-4.23%	-7.10%	Upgrade
FCF Yield	0.62%	0.44%	-3.09%	-2.75%	0.16%	-6.05%	Upgrade
Buyback Yield / Dilution	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%	Upgrade
Total Shareholder Return	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.